Overview

Mapracorat Ophthalmic Suspension for the Treatment of Ocular Inflammation Following Cataract Surgery

Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
The objective of this clinical study is to compare the safety and efficacy of Mapracorat Ophthalmic Suspension, 3% to vehicle for the treatment of postoperative inflammation and pain following cataract surgery.
Phase:
Phase 3
Details
Lead Sponsor:
Bausch & Lomb Incorporated